Department of Pediatric Hemato-Oncology, Ghent University Hospital, De Pintelaan 185, 9000 Ghent, Belgium.
Int J Clin Pharm. 2011 Aug;33(4):597-8. doi: 10.1007/s11096-011-9519-9.
Children with high-risk neuroblastoma are treated with polychemotherapy, surgery, radiotherapy and even autologous stem-cell transplantation. On top of this complex treatment, most children also receive 13-cis retinoic acid as differentiation agent. As no suitable pharmaceutical formulation is available so far, there are often problems with the administration of the product in children. The present report describes some practical recommendations for the administration of isotretinoin in children treated for high-risk neuroblastoma.
高危神经母细胞瘤患儿接受多药化疗、手术、放疗，甚至自体造血干细胞移植。在此复杂治疗基础上，大多数患儿还接受 13-顺式维甲酸作为分化剂治疗。由于目前尚无合适的药物制剂，患儿用药常常存在问题。本报告介绍了高危神经母细胞瘤患儿接受异维 A 酸治疗时的一些给药实用建议。
